MRNA
USDModerna Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$24.640
Kõrge
$25.150
Madal
$23.710
Maht
13.75M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
9.3B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
11.01M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk
Here are five key things investors need to know to start the trading day.
UBS Maintains Buy on Moderna, Lowers Price Target to $40
UBS analyst Eliana Merle maintains Moderna with a Buy and lowers the price target from $70 to $40.
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers
JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $25
JP Morgan analyst Jessica Fye maintains Moderna with a Underweight and lowers the price target from $26 to $25.
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance.
Moderna to Host Investor Event - Analyst Day
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.The event will include
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patientsCompany does not anticipate any impact to its 2025
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.